Loaded cached credentials.
I will now review the Tier 3 claims and challenge the Quorum verdicts, focusing on clinical accuracy and neuromodesty.

### Research Phase: Verifying Scientific Claims

I need to check the specific details for several claims, particularly the Shannon 1992 reference and the current status of BCI for withdrawal and gait.

1.  **Shannon 1992**: Does it discuss thermal limits or just electrical charge limits? (Usually electrical: $log(D) = k - log(Q)$).
2.  **M1 for Gait**: Is M1 the primary target or is it usually STN/GPi (DBS) or Spinal Cord?
3.  **Withdrawal Management**: What is the actual evidence for "BCI-mediated" (closed-loop) withdrawal management?
4.  **Fatigue Override**: Are there any studies supporting "overriding structural limits" via M1 stimulation? This sounds like a safety hazard/overclaim.

I'll use Google Search to verify these specific points.
Attempt 1 failed: You have exhausted your capacity on this model. Your quota will reset after 1s.. Retrying after 5684ms...
I have reviewed the Tier 3 claims and the Quorum verdicts. While the swarm correctly identified several qualifications, they were too lenient on technical inaccuracies regarding physiological limits and specific citations.

### Adversarial Review of Quorum Verdicts

| # | Your Verdict | Agree with Swarm? | Your Concern | Recommended Action |
|---|---|---|---|---|
| 1 | **OVERCLAIM** | No | "Emerging research" is still too broad. "Deployed" implies commercial/clinical standard of care, which does not exist for subvocalization BCIs. | **QUALIFY** to "Experimental Prototype (e.g., MIT AlterEgo)." |
| 2 | **MISIDENTIFIED** | Partially | M1 is rarely the primary target for gait *correction* (usually STN for DBS or Spinal Cord for paralysis). Using M1 as the benchmark is clinically atypical. | **QUALIFY** and specify clinical targets (STN/SCS). |
| 3 | **EXPERIMENTAL** | Partially | "BCI-mediated" implies a level of neural closed-loop control that is currently limited to Phase I/II NAc-DBS trials for addiction. | **QUALIFY** as "Phase I Clinical Research only." |
| 4 | **VIOLATES NEUROMODESTY** | No | The swarm was too lenient. "Overriding structural limits" is physiologically impossible and suggests "superhuman" tropes that undermine QIF's scientific credibility. | **REMOVE** "structural limits" entirely; keep central fatigue. |
| 5 | **FACTUAL ERROR** | No | **Shannon (1992)** defines electrical safety limits ($k$-value), NOT thermal limits. Attributing 41°C to Shannon is a fundamental citation error. | **REPLACE** citation with standard thermal damage models (e.g., CEM43). |
| 6 | **HIGH RISK** | Partially | Stimulating VTA/NAc for "safety" parameters is highly speculative given the high individual variability in reward circuitry. | **QUALIFY** with "Requires subject-specific calibration." |
| 7 | **INCOMPLETE** | Partially | 10-20 year lifetimes apply to DBS leads/pacemakers, but **not** to high-density recording arrays (e.g., Utah array), which often fail within 1-2 years due to gliosis. | **QUALIFY** by electrode type (Macroscopic vs. Microscopic). |
| 8 | **UNSTABLE** | Yes | Neural biomarkers (P300, etc.) are notoriously sensitive to circadian rhythms, caffeine, and stress. | **QUALIFY** as "Session-specific; requires frequent recalibration." |
| 9 | **PROPOSED** | Yes | This is a framework design choice, not a biological constant. | **LABEL** as "Proposed System Parameter." |
| 10 | **PHILOSOPHICAL** | Yes | No clinical precedent for a 10% threshold. It is a heuristic for ethical modeling. | **LABEL** as "Proposed Neuroethical Metric." |
| 11 | **INTERNAL** | Yes | Valid as a software benchmark for the Forge v1.0 PoC. | **KEEP** (Internal Benchmark). |
| 12 | **INTERNAL** | Yes | Valid as a software benchmark. | **KEEP** (Internal Benchmark). |
| 13 | **VALID** | Yes | Standard taxonomic mapping exercise. | **KEEP**. |
| 14 | **PROPOSED** | Yes | Framework-specific weighting. | **LABEL** as "Proposed QIF Metric." |
| 15 | **PROPOSED** | Yes | Categorical expansion for neurosecurity. | **LABEL** as "Proposed QIF Extension." |
| 16 | **STALE** | Yes | The technique count has expanded since the initial draft. | **RECOMPUTE** and sync with `atlas/` data. |
| 17 | **VALID** | Yes | Fundamental papers for neural plasticity. | **KEEP**. |

### Key Findings & Required Changes
1.  **Citation Correction**: Claim #5 is a "hallucinated" association. Shannon 1992 is exclusively about electrical charge density. It must not be used to justify thermal thresholds.
2.  **Neuromodesty Enforcement**: Claim #4 must be pruned. Claiming a BCI can override "structural limits" (bone/tendon strength) is a safety hazard and scientifically unsound. It should focus exclusively on "central fatigue" (perceived effort).
3.  **Terminology Precision**: "Deployed" (Claim #1) must be replaced with "Experimental" to avoid misleading readers about the availability of subvocalization technology.
4.  **Electrode Lifetimes**: Claim #7 needs a major caveat. The 10-20 year claim is true for cardiac/DBS but highly misleading for the high-bandwidth BCIs (Neuralink, Blackrock) that QIF primarily targets.
